Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
MYOS's Cash to Debt is ranked higher than
95% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MYOS: No Debt )
MYOS' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: No Debt

Equity to Asset 0.95
MYOS's Equity to Asset is ranked higher than
99% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. MYOS: 0.95 )
MYOS' s 10-Year Equity to Asset Range
Min: 0.17   Max: 0.96
Current: 0.95

0.17
0.96
F-Score: 4
Z-Score: 81.07
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -332.79
MYOS's Operating margin (%) is ranked lower than
57% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. MYOS: -332.79 )
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.42   Max: -332.79
Current: -332.79

-4642.42
-332.79
Net-margin (%) -429.17
MYOS's Net-margin (%) is ranked lower than
57% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MYOS: -429.17 )
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.54   Max: -429.17
Current: -429.17

-5653.54
-429.17
ROE (%) -63.15
MYOS's ROE (%) is ranked lower than
55% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYOS: -63.15 )
MYOS' s 10-Year ROE (%) Range
Min: -1178.32   Max: -63.15
Current: -63.15

-1178.32
-63.15
ROA (%) -59.95
MYOS's ROA (%) is ranked lower than
56% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. MYOS: -59.95 )
MYOS' s 10-Year ROA (%) Range
Min: -600   Max: -59.95
Current: -59.95

-600
-59.95
ROC (Joel Greenblatt) (%) -1001.65
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. MYOS: -1001.65 )
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4837.89   Max: -1001.65
Current: -1001.65

-4837.89
-1001.65
EBITDA Growth (%) 245.50
MYOS's EBITDA Growth (%) is ranked higher than
99% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYOS: 245.50 )
MYOS' s 10-Year EBITDA Growth (%) Range
Min: -27.9   Max: 508.7
Current: 245.5

-27.9
508.7
EPS Growth (%) 276.20
MYOS's EPS Growth (%) is ranked higher than
99% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MYOS: 276.20 )
MYOS' s 10-Year EPS Growth (%) Range
Min: -37   Max: 510
Current: 276.2

-37
510
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.00
MYOS's P/B is ranked lower than
61% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. MYOS: 6.00 )
MYOS' s 10-Year P/B Range
Min: 0.08   Max: 16.26
Current: 6

0.08
16.26
P/S 0.20
MYOS's P/S is ranked higher than
98% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. MYOS: 0.20 )
MYOS' s 10-Year P/S Range
Min: 0.16   Max: 500
Current: 0.2

0.16
500
EV-to-EBIT 125.00
MYOS's EV-to-EBIT is ranked lower than
75% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. MYOS: 125.00 )
MYOS' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 1.7
Current: 125

0.1
1.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.40
MYOS's Price/Net Cash is ranked lower than
59% of the 214 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.10 vs. MYOS: 16.40 )
MYOS' s 10-Year Price/Net Cash Range
Min: 5.99   Max: 10
Current: 16.4

5.99
10
Price/Net Current Asset Value 15.00
MYOS's Price/Net Current Asset Value is ranked lower than
64% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. MYOS: 15.00 )
MYOS' s 10-Year Price/Net Current Asset Value Range
Min: 5.62   Max: 178.85
Current: 15

5.62
178.85
Price/Tangible Book 11.10
MYOS's Price/Tangible Book is ranked lower than
73% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. MYOS: 11.10 )
MYOS' s 10-Year Price/Tangible Book Range
Min: 4.9   Max: 80.17
Current: 11.1

4.9
80.17
Price/Median PS Value 0.60
MYOS's Price/Median PS Value is ranked higher than
92% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. MYOS: 0.60 )
MYOS' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 18.6
Current: 0.6

0.3
18.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
MYOS Corp is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide